Dr. Duane Nash

Duane Nash, M.D., J.D., M.B.A, joined Immunic’s board as its chairman in 2019. From 2012 to 2019, Dr. Nash served in various leadership roles at Vital Therapies (Nasdaq: VTL), most recently as its Chief Executive Officer. Additional roles included Medical Director, Executive Vice President, Chief Business Officer and President. Prior to joining Vital Therapies, Dr. Nash held various positions at Wedbush PacGrowth Life Sciences, an investment bank, where he was employed from 2009 to 2012, serving most recently as Senior Vice President in Equity Research. Before that, he was a research analyst at Pacific Growth Equities, an investment bank, which was acquired by Wedbush in 2009.

Dr. Nash also practiced as an attorney from 2002 to 2008, most recently at the law firm of Davis Polk & Wardwell, where he focused on intellectual property litigation and corporate matters. Dr. Nash served on the board of directors of Aerpio Pharmaceuticals (Nasdaq: ARPO) from 2012 to 2017, and Akebia Therapeutics (Nasdaq: AKBA) from 2013 to 2018.

Dr. Nash earned a B.A. in biology from Williams College, an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an M.B.A. from the University of Oxford. Dr. Nash completed his internship in general surgery at the University of California, San Francisco.

Dr. Nash has been a member of Immunic’s Board since January 2019 and has served as Chairman of the board of directors since April 2019, and as Executive Chairman since April 2020.